‘It’s working!’ Columbus cancer center is first in Georgia to administer this new therapy
Susan Williams,seated center, a patient at the John B. Amos Cancer Center in Columbus, Georgia, is receiving a new cancer treatment known as Bispecific T-Cell Engager (BiTE) therapies on Feb. 11, 2025 ...
Scientists uncover key mechanism linking microtubules and chemotherapy, enhancing cancer drug efficacy
A joint research team from the LKS Faculty of Medicine (HKUMed) and the Faculty of Science at the University of Hong Kong has uncovered an unexpected interaction between chemotherapeutic agents and a ...
Cure Today5d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.
Cure Today8d
Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...
BioWorld8d
Henlius lands European approval of PD-1 lung cancer drug
The European Commission on Feb. 5 cleared Shanghai Henlius Biotech Inc.’s serplulimab (HLX-02) under the brand name of Hetronifly as a first-line combination therapy with carboplatin and etoposide to ...
360dx9d
Imagene, Tempus AI to Collaborate on AI-Based Lung Cancer Diagnostics
Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.
中国日报网9d
Shanghai Henlius Biotech's lung cancer drug gets EU approval
Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti-PD-1 mAb, ...
Immuneering and Regeneron partner on lung cancer trial
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...
GlobalData on MSN11d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone
A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
Business Wire17d
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate ...
The assets being acquired include a Phase 2 lung cancer and Phase1 prostate cancer ... of shares to raise capital under its equity line of credit so long as the price of the common stock is ...
The Dominion Post21d
WVU Cancer Institute offers pioneering lung cancer treatment
Small-cell lung cancer is the deadliest form, he said. Imdelltra is FDA approved as a treatment when the cancer has metastasized and the patient has progressed beyond first-line treatment ...
Business Wire24d
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
We look forward to continuing to advance the clinical development of this promising asset across lines of therapy in ... About Small Cell Lung Cancer (SCLC) SCLC is one of the most aggressive ...